Highlights NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
12.8 ^USD	+1.31%		+8.20%	-14.27%

Apr. 24	NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	CI
Apr. 10	Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	Apr. 24	CI
NovoCure Says New Data Show TTFields' Potential Therapeutic Effects in Pancreatic Cancer	Apr. 05	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Board Governor Waller's Speech	Mar. 27	MT
Novocure Q4 Net Loss Widens, Revenue Rises	Feb. 22	MT
Earnings Flash (NVCR) NOVOCURE Reports Q4 Revenue $133.8M	Feb. 22	MT
NovoCure Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
NovoCure Says US FDA Accepts Its Premarket Approval Application for Tumor Treating Fields in Lung Cancer; Shares Rise	Jan. 18	MT
Novocure Shares Rise 17% After FDA Accepts Pre-Market Application	Jan. 18	DJ
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer	Jan. 18	CI
NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma	Jan. 09	CI
NovoCure Reports Higher Q4 Preliminary Revenue; Shares Rise	Jan. 08	MT
Novocure Preliminary Full Year 2023 Net Revenues Of $509 Mln And Q4 Net Revenues Of $134 Mln	Jan. 08	RE
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability	Nov. 28	CI
Earnings Flash (NVCR) NOVOCURE Reports Q3 Revenue $127.3M, vs. Street Est of $128.8M	23-10-26	MT
NovoCure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
NovoCure to Establish Tumor Treating Fields Research Program With Stanford University	23-10-12	MT
Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program	23-10-12	CI
Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies	23-08-29	CI
Earnings Flash (NVCR) NOVOCURE Posts Q2 Revenue $126.1M, vs. Street Est of $124.3M	23-07-27	MT
NovoCure Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Highlights

Filters